title: High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas.
abstract: Neuroblastoma (NB) is a common pediatric tumor of neural crest origin that is biologically and clinically heterogeneous. EPH family receptor tyrosine kinases and ephrin ligands play fundamental roles in neurodevelopmental processes. Recently, we found that NB cell lines expressed several EPHB and EFNB transcripts, which encode EPHB subgroup receptors and ephrin-B subgroup ligands, respectively. To explore the role of EPHB receptors and ephrin-B ligands in the biology of NB, we examined the expression of EPHB and EFNB transcripts in 47 primary NB specimens. Multiple EPHB and EFNB transcripts were expressed in all of the NB tumors examined, suggesting the involvement of these transcripts in modulating the biological behavior of NB. Higher levels of EPHB6, EFNB2, and EFNB3 expression were found in low-stage tumors (stage 1, 2, and 4S) than in advanced-stage tumors (stage 3 and 4; P = 0.0013, P = 0.0048, and P = 0.027, respectively). Expression of TrkA, a well-established prognostic marker of favorable NB, was positively correlated with EPHB6, EFNB2, and EFNB3 expression (P < 0.0001, P = 0.0019, and P = 0.0001, respectively). MYCN-amplified tumors expressed lower levels of EPHB6, EFNB2, EFNB3, and TrkA transcripts compared to nonamplified tumors (P = 0.0006, P = 0.0023, P = 0.0048, and P = 0.0001, respectively). These data suggest that high-level expression of EPHB6, EFNB2, and EFNB3 is associated with favorable NB and that low-level expression of EPHB6, EFNB2, and EFNB3 correlates with aggressive MYCN-amplified NB. Thus, EPHB6, EFNB2, and EFNB3 may have biological relevance in NB. Further investigation on the biology of these genes may help provide insight into the treatment of NB.
authors.affiliation: Division of Oncology, The Children's Hospital of Philadelphia, Abramson Research Center, Pennsylvania 19104-4318, USA.
authors.forename: X X
authors.initials: XX
authors.lastname: Tang
authors.forename: A E
authors.initials: AE
authors.lastname: Evans
authors.forename: H
authors.initials: H
authors.lastname: Zhao
authors.forename: A
authors.initials: A
authors.lastname: Cnaan
authors.forename: W
authors.initials: W
authors.lastname: London
authors.forename: S L
authors.initials: SL
authors.lastname: Cohn
authors.forename: G M
authors.initials: GM
authors.lastname: Brodeur
authors.forename: N
authors.initials: N
authors.lastname: Ikegaki
mesh_terms: D036388:Ephrin-B2; D036389:Ephrin-B3; D016259:Genes, myc / Q000235:genetics; D006801:Humans; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D011379:Prognosis; D012313:RNA / Q000096:biosynthesis; D020794:Receptor Protein-Tyrosine Kinases / Q000096:biosynthesis*; D020917:Receptor, trkA / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D036388:Ephrin-B2; D036389:Ephrin-B3; D012313:RNA; D020794:Receptor Protein-Tyrosine Kinases; D020917:Receptor, trkA